Relapsed/refractory clinically advanced (CA) testicular non-seminomatous germ cell tumors (NSGCT): A genomic landscape study.
Valentina Tateo(Vita-Salute San Raffaele University), Andrea Necchi(Vita-Salute San Raffaele University), A. Kamat(The University of Texas MD Anderson Cancer Center), Antonio Cigliola(Vita-Salute San Raffaele University), Douglas I. Lin(Foundation Medicine (United States)), Michela Piacentini(Azienda Ospedaliera Universitaria Integrata Verona), Sumanta Kumar Pal(City Of Hope National Medical Center), Neeraj Agarwal(Huntsman (United States)), Shilpa Gupta(Cleveland Clinic), J L Lortat Jacob(SUNY Upstate Medical University), Petros Grivas(University of Washington), Philippe E. Spiess(Moffitt Cancer Center), Hannan Goldberg(SUNY Upstate Medical University), Brigida Anna Maiorano(Vita-Salute San Raffaele University), Jeffrey S. Ross(SUNY Upstate Medical University), Roger Li(Moffitt Cancer Center), Dean C. Pavlick(Foundation Medicine (United States)), Gennady Bratslavsky(SUNY Upstate Medical University), Liang Cheng(Brown University), Alina Basnet(Cancer Clinic)
Cited by 0
Related Papers
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
|Nature Reviews Clinical Oncology|2021|140
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
|Cancer Discovery|2024|137